Literature DB >> 24773389

Fc receptor is not required for inducing antibodies but plays a critical role in conferring protection after influenza M2 vaccination.

Yu-Na Lee1, Young-Tae Lee, Min-Chul Kim, Hye Suk Hwang, Jong Seok Lee, Ki-Hye Kim, Sang-Moo Kang.   

Abstract

The ectodomain of matrix protein 2 (M2e) of influenza virus is considered a rational target for a universal influenza A vaccine. To better understand M2e immune-mediated protection, Fc receptor common γ chain deficient (FcRγ(-/-) ) and wild-type mice were immunized with a tandem repeat of M2e presented on virus-like particles (M2e5x VLP). Levels of M2e-specific antibodies that were induced in FcRγ(-/-) mice after immunization with M2e5x VLP were similar to those in wild-type mice. In addition, M2e antibodies induced in FcRγ(-/-) mice were found to be equally protective as those induced in wild-type mice. However, M2e5x VLP-immunized FcRγ(-/-) mice were not well protected, as shown by severe weight loss, higher lung viral titres and interleukin-6 inflammatory cytokine production upon influenza virus challenge compared with M2e5x VLP-immunized wild-type mice. Importantly, FcRγ(-/-) mice that were immunized with inactivated influenza virus induced haemagglutination inhibition activity and were well protected without a significant weight loss. Interestingly, interferon-γ-producing CD4 T and CD8 T cells were found to be prevalent in lungs from M2e5x VLP-immunized FcRγ(-/-) mice, which appeared to be correlated with a faster recovery after infection. These results indicate that Fc receptors play a primary role in conferring M2e-specific antibody-mediated protection whereas T cells may contribute to the recovery at later stages of infection.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  Fc receptor; T cells; influenza virus; matrix protein 2 ectodomain antibodies; matrix protein 2 ectodomain virus-like particles

Mesh:

Substances:

Year:  2014        PMID: 24773389      PMCID: PMC4172145          DOI: 10.1111/imm.12310

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  36 in total

1.  Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use.

Authors:  N Hehme; H Engelmann; W Kuenzel; E Neumeier; R Saenger
Journal:  Virus Res       Date:  2004-07       Impact factor: 3.303

2.  Human memory CTL response specific for influenza A virus is broad and multispecific.

Authors:  C Gianfrani; C Oseroff; J Sidney; R W Chesnut; A Sette
Journal:  Hum Immunol       Date:  2000-05       Impact factor: 2.850

3.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.

Authors:  R A Lamb; S L Zebedee; C D Richardson
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

4.  Virus-like particles containing multiple M2 extracellular domains confer improved cross-protection against various subtypes of influenza virus.

Authors:  Min-Chul Kim; Jae-Min Song; Eunju O; Young-Man Kwon; Youn-Jeong Lee; Richard W Compans; Sang-Moo Kang
Journal:  Mol Ther       Date:  2012-12-18       Impact factor: 11.454

5.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

6.  Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

Authors:  Krystyna Mozdzanowska; JinQi Feng; Mark Eid; Goran Kragol; Mare Cudic; Laszlo Otvos; Walter Gerhard
Journal:  Vaccine       Date:  2003-06-02       Impact factor: 3.641

7.  Evolutionary analysis of the influenza A virus M gene with comparison of the M1 and M2 proteins.

Authors:  T Ito; O T Gorman; Y Kawaoka; W J Bean; R G Webster
Journal:  J Virol       Date:  1991-10       Impact factor: 5.103

8.  Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions.

Authors:  S L Zebedee; R A Lamb
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

9.  Isolation and characterization of conglutinin as an influenza A virus inhibitor.

Authors:  N Wakamiya; Y Okuno; F Sasao; S Ueda; K Yoshimatsu; M Naiki; T Kurimura
Journal:  Biochem Biophys Res Commun       Date:  1992-09-30       Impact factor: 3.575

10.  Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge.

Authors:  B S Bender; T Croghan; L Zhang; P A Small
Journal:  J Exp Med       Date:  1992-04-01       Impact factor: 14.307

View more
  30 in total

1.  Complement C3 Plays a Key Role in Inducing Humoral and Cellular Immune Responses to Influenza Virus Strain-Specific Hemagglutinin-Based or Cross-Protective M2 Extracellular Domain-Based Vaccination.

Authors:  Yu-Jin Kim; Ki-Hye Kim; Eun-Ju Ko; Min-Chul Kim; Yu-Na Lee; Yu-Jin Jung; Young-Tae Lee; Young-Man Kwon; Jae-Min Song; Sang-Moo Kang
Journal:  J Virol       Date:  2018-09-26       Impact factor: 5.103

Review 2.  The Unexpected Impact of Vaccines on Secondary Bacterial Infections Following Influenza.

Authors:  Amber M Smith; Victor C Huber
Journal:  Viral Immunol       Date:  2017-11-17       Impact factor: 2.257

Review 3.  Fc or not Fc; that is the question: Antibody Fc-receptor interactions are key to universal influenza vaccine design.

Authors:  Sinthujan Jegaskanda; Hillary A Vanderven; Adam K Wheatley; Stephen J Kent
Journal:  Hum Vaccin Immunother       Date:  2017-03-23       Impact factor: 3.452

4.  A Novel Vaccination Strategy Mediating the Induction of Lung-Resident Memory CD8 T Cells Confers Heterosubtypic Immunity against Future Pandemic Influenza Virus.

Authors:  Yu-Na Lee; Young-Tae Lee; Min-Chul Kim; Andrew T Gewirtz; Sang-Moo Kang
Journal:  J Immunol       Date:  2016-02-10       Impact factor: 5.422

5.  Neuraminidase expressing virus-like particle vaccine provides effective cross protection against influenza virus.

Authors:  Ki-Hye Kim; Young-Tae Lee; Soojin Park; Yu-Jin Jung; Youri Lee; Eun-Ju Ko; Yu-Jin Kim; Xuguang Li; Sang-Moo Kang
Journal:  Virology       Date:  2019-07-08       Impact factor: 3.616

6.  Roles of antibodies to influenza A virus hemagglutinin, neuraminidase, and M2e in conferring cross protection.

Authors:  Yu-Jin Kim; Eun-Ju Ko; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Yu-Jin Jung; Sang-Moo Kang
Journal:  Biochem Biophys Res Commun       Date:  2017-09-05       Impact factor: 3.575

7.  Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.

Authors:  Yu-Na Lee; Min-Chul Kim; Young-Tae Lee; Yu-Jin Kim; Jongsang Lee; Cheol Kim; Suk-Hoon Ha; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2015-08-04       Impact factor: 5.970

8.  Effects of MF59 Adjuvant on Induction of Isotype-Switched IgG Antibodies and Protection after Immunization with T-Dependent Influenza Virus Vaccine in the Absence of CD4+ T Cells.

Authors:  Eun-Ju Ko; Young-Tae Lee; Ki-Hye Kim; Yu-Jin Jung; Youri Lee; Timothy L Denning; Sang-Moo Kang
Journal:  J Virol       Date:  2016-07-11       Impact factor: 5.103

9.  Immunogenicity and efficacy of replication-competent recombinant influenza virus carrying multimeric M2 extracellular domains in a chimeric hemagglutinin conjugate.

Authors:  Min-Chul Kim; Yu-Na Lee; Yu-Jin Kim; Hyo-Jick Choi; Ki-Hye Kim; Youn-Jeong Lee; Sang-Moo Kang
Journal:  Antiviral Res       Date:  2017-10-26       Impact factor: 5.970

Review 10.  Requirement of Fc-Fc Gamma Receptor Interaction for Antibody-Based Protection against Emerging Virus Infections.

Authors:  Shamus P Keeler; Julie M Fox
Journal:  Viruses       Date:  2021-05-31       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.